On February 4, 2021 Chugai Pharmaceutical Co., Ltd. reported that there is a difference regarding the individual financial results (Japanese standard) for the year ended December 2020 (Jan. 1, 2020– Dec. 31, 2020) as compared to the actual results for the previous year (Jan. 1, 2019 – Dec. 31, 2019) (Press release, Chugai, FEB 4, 2021, View Source [SID1234574604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Difference between the actual results for the year ended December 2020 and the actual results for the previous year

*Effective July 1, 2020, Chugai has implemented a three-for-one stock split of its common stock. "Earnings per share" are calculated based on the assumption that the stock split was implemented at the beginning of the previous year.

2. Reasons for the difference occurring
The difference occurred mainly due to increase in exports to Roche, increase in royalties and other operating income, and improvement in cost to sales ratio due to changes in product mix, etc.